Liver Diseases  >>  refametinib (BAY86-9766)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
refametinib (BAY86-9766) / Bayer
BASIL, NCT01204177: Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer.

Checkmark In combination with sorafenib for Asian pts with unresectable HCC
Oct 2014 - Oct 2014: In combination with sorafenib for Asian pts with unresectable HCC
Checkmark P2 data-ASCO
Jun 2012 - Jun 2012: P2 data-ASCO
Completed
2
70
RoW
BAY86-9766 MEK Inhibitor + Sorafenib
Bayer
Carcinoma, Hepatocellular
08/11
08/13

Download Options